FORM 3

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104 Estimated average burden

hours per response: 0.5

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

			or Secu	on 3	0(11) 01 11	ne investment Company Ac	ιo	11940				
1. Name and Address of Reporting Person*  Hana Immunotherapeutics  LLC			Requiring S (Month/Day	2. Date of Event Requiring Statement (Month/Day/Year) 03/20/2023		3. Issuer Name <b>and</b> Ticker Zura Bio Ltd [ ZUF			Symbol			
(Last) (First) (Middle) 16 CENTERPOINTE DR. #625			_				g F	10% Owner		If Amendment, Date of Original Filed (Month/Day/Year)      Individual or Joint/Group Filing		
(Street) LA PALMA CA		90623	_			Officer (give title below)			specify	(Ch	(Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person	
(City) (Sta	ite)	(Zip)										
Table I - Non-Derivative Securities Beneficially Owned												
1. Title of Security (Instr. 4)					E	2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)			irect direct	4. Nature of Indirect Beneficial Ownership (Instr. 5)		
Class A Ordinary Shares, par value \$0.0001						5,404,274(1)(2)		Ι	D			
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)												
[			2. Date Exerc Expiration Day/\(Month/Day/\)	ate		3. Title and Amount of Secur Underlying Derivative Securi (Instr. 4)					5. Ownership Form: Direct (D)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
			Date Exercisable	Ex Da	piration te	Title	N O	Amount or Number of Shares	Derivat Securit	ive	or Indirect (I) (Instr. 5)	5,
1. Name and Addrese Hana Immun		-	<u>C</u>									
(Last) 16 CENTERPO	(First)	,	iddle)									
(Street) LA PALMA	CA	90	0623									
(City)	(State)	(Zi	p)									
1. Name and Address of Reporting Person*  Kim Chris												
(Last) (First) (Midd 16 CENTERPOINTE DR. #625			iddle)									
(Street) LA PALMA	CA	90	0623									

## Explanation of Responses:

(State)

(Zip)

(City)

("JATT"), JATT Merger Sub, a Cayman Islands exempted company and wholly owned subsidiary of JATT, JATT Merger Sub 2, a Cayman Islands exempted company and wholly owned subsidiary of JATT, and Zura Bio Holdings Ltd, a Cayman Islands exempted company (the "Business Combination"). The Reporting Person received the reported shares for its shares in Zura at the Exchange Ratio, as defined in the Business Combination Agreement, upon the closing of the Business Combination.

2. The shares are held of record by Hana Immunotherapeutics LLC ("Hana"). Mr. Chris Kim is is the manager of Hana and as such has voting and investment power over the shares held by Hana. Mr. Kim disclaims beneficial ownership over all shares held by Hana over which he does not have a pecuniary interest.

 By: /s/ Chris Kim
 04/04/2023

 /s/ Chris Kim
 04/04/2023

 \*\* Signature of Reporting Person
 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.